alpha-Glucosidases [CS] class drugs

8 results
  • aldurazyme - laronidase injection, solution, concentrate

    (Laronidase)
    Genzyme Corporation
    Aldurazyme treats adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), and Scheie form MPS I patients with moderate to severe symptoms.
  • elaprase - idursulfase solution, concentrate

    (Idursulfase)
    Takeda Pharmaceuticals America, Inc.
    Elaprase treats Hunter syndrome (MPS II) in patients 16 months and older. Improves walking capacity in patients 5 years and older; reduces spleen volume in younger patients. Safety and efficacy not established under 16 months.
  • elfabrio - pegunigalsidase alfa injection, solution, concentrate

    (Pegunigalsidase Alfa)
    Chiesi Usa, Inc.
    Elfabrio is indicated for the treatment of adults with confirmed Fabry disease.
  • lumizyme - alglucosidase alfa injection, powder, for solution

    (Alglucosidase Alfa)
    Genzyme Corporation
    Lumizyme is indicated for patients with Pompe disease (acid alpha-glucosidase deficiency), a rare genetic condition affecting lysosomal glycogen breakdown.
  • naglazyme - galsulfase solution

    (Galsulfase)
    Biomarin Pharmaceutical Inc.
    Naglazyme is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome), improving walking and stair-climbing capacity.
  • nexviazyme - avalglucosidase alfa - ngpt injection, powder, lyophilized, for solution

    (Avalglucosidase Alfa-Ngpt)
    Genzyme Corporation
    Nexviazyme treats late-onset Pompe disease (lysosomal acid alpha-glucosidase deficiency) in patients 1 year and older.
  • vimizim - elosulfase alfa injection, solution, concentrate

    (Elosulfase Alfa)
    Biomarin Pharmaceutical Inc.
    Vimizim (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).